Gasser Peter, Liechti Matthias E, Holze Friederike
Private Practitioner, Solothurn, Switzerland.
Clinical Pharmacology and Toxicology, University Hospital Basel and University of Basel, Basel, Switzerland.
Front Psychiatry. 2025 Feb 3;16:1513022. doi: 10.3389/fpsyt.2025.1513022. eCollection 2025.
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of methylenedioxymethamphetamine (MDMA). At the beginning of treatment, the patient did not experience any acute subjective effects of LSD at a dose of 200 µg. After increasing the LSD dose to 400 µg, he experienced subjective acute effects, and the first lasting therapeutic effects were observed. After changing from LSD to MDMA at both high doses (150-175 mg) and repeated low doses (12.5-25 mg), the patient exhibited marked improvements in neuropathic pain that were sustained even after stopping repeated MDMA treatment. MDMA mini/microdosing has not yet been broadly investigated. This case documents benefits of low doses of MDMA for the treatment of a pain disorder. Further research is needed on effects of MDMA on pain.
一名64岁男性患者，在经历创伤性生活事件及肿瘤化疗后出现神经性疼痛，接受了中高剂量的麦角酸二乙酰胺（LSD）以及高剂量和微剂量的亚甲二氧基甲基苯丙胺（MDMA）治疗。治疗开始时，患者服用200微克剂量的LSD未出现任何急性主观效应。将LSD剂量增至400微克后，他出现了主观急性效应，并观察到了首个持久的治疗效果。在从LSD换用高剂量（150 - 175毫克）和重复低剂量（12.5 - 25毫克）的MDMA后，患者神经性疼痛有显著改善，即使在停止重复MDMA治疗后仍持续存在。MDMA小剂量/微剂量治疗尚未得到广泛研究。该病例记录了低剂量MDMA治疗疼痛障碍的益处。需要进一步研究MDMA对疼痛的影响。
